News & Publications

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • KemPharm Announces Positive Topline Results from Intranasal Human Abuse Potential Trial of KP415 Prodrug

  • KemPharm Announces Positive Topline Results from Oral Human Abuse Potential Trial of KP415 Prodrug

  • KemPharm to Present at Two Healthcare Investor Conferences During September 2018

  • KemPharm, Inc. Reports Second Quarter 2018 Results

  • KemPharm to Present at Canaccord Genuity 38th Annual Growth Conference

  • KemPharm, Inc. to Report Second Quarter 2018 Results

  • KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD; KP415 Successfully Meets Primary Efficacy Endpoint

  • KemPharm Announces Positive, Topline Results from an IV Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results

  • KemPharm, Inc. to Report First Quarter 2018 Results

  • KemPharm Reports Fourth Quarter and Year End 2017 Results

  • KemPharm, Inc. to Report Fourth Quarter and Year End 2017 Results

  • Positive Topline Results from KP415 PK Study in Children/Adolescents With ADHD